These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34778040)

  • 41. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
    Ha KH; Kim DJ; Choi YJ
    J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
    Emral R; Haymana C; Demirci I; Tasci I; Sahin M; Cakal E; Ata N; Unluturk U; Demir T; Ertugrul D; Sahin I; Atmaca A; Celik O; Caglayan M; Arga KY; Dagdelen S; Salman S; Satman I; Sonmez A
    Diabetes Ther; 2021 Nov; 12(11):2857-2870. PubMed ID: 34398433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Front Pharmacol; 2021; 12():689885. PubMed ID: 34650428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
    Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
    Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study.
    Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1629-1639. PubMed ID: 31646732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study.
    Aloe S; Filliter C; Salmasi S; Igweokpala S; Yu OHY; Tagalakis V; Filion KB
    Br J Clin Pharmacol; 2023 Sep; 89(9):2902-2914. PubMed ID: 37183930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
    JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 52. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
    Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
    J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
    Rathmann W; Kostev K
    J Diabetes Complications; 2017 Apr; 31(4):687-692. PubMed ID: 28169131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
    Vistisen D; Carstensen B; Elisabetta P; Lanzinger S; Tan EC; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Núñez J; Ha KH; Halvorsen S; Langslet G; Karasik A; Nyström T; Niskanen L; Guleria S; Klement R; Carrasco M; Foersch J; Shay C; Koeneman L; Hoti F; Farsani SF; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; ;
    Cardiovasc Diabetol; 2023 Aug; 22(1):233. PubMed ID: 37653496
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
    McCormick N; Yokose C; Wei J; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; Zhang Y; Choi HK
    Ann Intern Med; 2023 Aug; 176(8):1067-1080. PubMed ID: 37487215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
    Saito A; Kitayama J; Horie H; Koinuma K; Kawashima R; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
    Cancer Res Commun; 2021 Nov; 1(2):106-114. PubMed ID: 36860286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.
    Ruan Z; Zou H; Lei Q; Ung COL; Shi H; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):555-574. PubMed ID: 35152812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.